

## **DSM Anti-Infectives India And Lupin Enter Into A Strategic Cooperation For Cephalosporins**

**September 02, 2005:** DSM Anti-Infectives India Ltd. and Lupin Limited have entered into a supply and marketing agreement for a strategic cooperation in the cephalosporins segment.

In recent years, both the companies have demonstrated their strength in this key segment and this strategic cooperation will further enable to strengthen their respective positions in this segment through enhanced utilisation of existing resources, with an enhanced market access.

Mr. N.V. Ramanan, Head of DSM Anti Infectives (Asia Pacific, Middle east, Africa) and Country representative of Royal DSM NV said “Cephalosporins is strategically an important segment and with this cooperation we look forward to working closely with Lupin and further enhance our market reach and leadership.”

Commenting on the development Mr. Satish Khanna, Group President API, Lupin Limited said “This development enhances our market reach and will enable us to optimally utilise our resources. We look forward to increase this cooperation over a wider product basket to bring synergetic advantages to both Lupin and DSM Anti-Infectives.”

### **About DSM Anti-Infectives India**

DSM Anti-Infectives India is a part of the business group DSM Anti-Infectives (global turnover of Euro 500 Million, whereas DSM group annual turnover is Euro 8 Billion), which holds a leadership position in the field of Active Pharmaceutical Ingredients for the  $\beta$ -Lactam industry.

### **About Lupin**

Headquartered in Mumbai, Lupin (<http://www.lupinworld.com>) develops, manufactures and markets generic intermediates, active pharmaceutical ingredients and finished dosages. Its FY 2004-05 revenues were Rs.12 billion.11 of Lupin's plants have been approved by the USFDA and two facilities have been approved by the UKMHRA